Back

Efficacy of sodium-glucose cotransporter 2 inhibitors for super-aged heart failure population

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Heart failure management in specific populations Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Jun-Ichi Noiri

Kobe University Graduate School of Medicine, Kobe (Japan)

9 More presentations in this session

Presentation thumbnail
Phenotypes of heart failure with preserved ejection fraction and effect of sodium-glucose cotransporter 2 inhibitors treatment
Doctor A. Sezaki (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
The relevant role of frailty in patients with transthyretin amyloidosis cardiomyopathy
Doctor B. Dal Passo (Ferrara, IT)
Abstract Slides Video
Presentation thumbnail
Role of comorbidities and weight variations in the survival of diabetic patients with heart failure
Professor O. Hanon (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Angiotensin receptor-neprilysin inhibitor-based therapy among adult heart failure patients with below normal systemic ventricular ejection fraction and complex congenital heart disease
Doctor D. Dela Cruz (Metro Manila, PH)
Abstract Slides Video
Presentation thumbnail
The effects of empagliflozin on ventricular arrhythmias in heart failure patients with an implantable cardioverter-defibrillator: a systematic review
Doctor M. Hunjul (Nablus, PS)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure management in specific populations

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of SGLT2 inhibitors in heart failure: real-world evidence in geriatric patients
thumbnail
Congress Presentation
Real-life data on the tolerability of SGLT2 inhibitors in elderly patients with heart failure
thumbnail
Congress Presentation
Effect of renin-angiotensin system inhibitors in elderly patients with heart failure and reduced ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources